Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

The safety and effectiveness of nilotinib in the treatment of unresponsive CML

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of using nilotinib (Tasigna) in patients with chronic myeloid leukemia (CML) unresponsive to other treatment. The study concluded that nilotinib is safe and effective in the treatment of CML unresponsive to imatinib (Gleevec). Some background Chronic myeloid leukemia is a cancer of the...

Read More

What is the evidence for and against green tea and tumeric in the management of CLL?

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the evidence for and against green tea and turmeric in the treatment of chronic lymphocytic leukemia (CLL). The study found that there is a lack of evidence of these treatments in treating CLL. Some background Complementary alternative medicine (CAM) are a commonly used group of practices and products that are...

Read More

Outcomes and management of CLL treated with venetoclax

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). Researchers found that venetoclax was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a type of cancer of the bone marrow that can lead to an abnormal immune system. Over...

Read More

Evaluating vascular safety of TK inhibitors in patients with chronic myeloid leukemia

Posted by on Aug 18, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...

Read More

Nilotinib versus imatinib in the treatment of CML

Posted by on Aug 13, 2018 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...

Read More

What major factors affect disease progression and outcome in adults with acute myeloid leukemia?

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...

Read More

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to identify the outcomes and prognostic factors following a stem cell transplant from a donor in adults with acute myeloid leukemia in their second complete remission (no sign of disease). The authors determined that this type of transplant was effective in these patients. Some background In adult patients with acute...

Read More